Condurangoglykosid A
CAS: 11051-90-4
Rif. 3D-LAA05190
| 5mg | Prezzo su richiesta | |
| 10mg | Prezzo su richiesta | |
| 25mg | Prezzo su richiesta | |
| 50mg | Prezzo su richiesta | |
| 100mg | Prezzo su richiesta |
Informazioni sul prodotto
- (3β,11α,12β,14β)-11-(Acetyloxy)-3-[(O-6-deoxy-3-O-methyl-β-<span class="text-smallcaps">D</smallcap>-allopyranosyl-(1→4)-O-2,6-dideoxy-3-O-methyl-β-<smallcap>D</smallcap>-arabino-hexopyranosyl-(1→4)-2,6-dideoxy-3-O-methyl-β-<smallcap>D</span>-ribo-hexopyranosyl)oxy]-14-hydroxy-12-[(1-oxo-3-phenyl-2-propen-1-yl)oxy]pregnan-20-one
- (3β,8xi,9xi,11α,12β,14β)-11-(acetyloxy)-3-{[6-deoxy-3-O-methyl-β-D-allopyranosyl-(1->4)-2,6-dideoxy-3-O-methyl-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-3-O-methyl-β-D-ribo-hexopyranosyl]oxy}-14-hydroxy-20-oxopregnan-12-yl (2E)-3-phenylprop-2-enoate
- Condurango glycoside A
- Pregnan-20-one, 11-(acetyloxy)-3-[(O-6-deoxy-3-O-methyl-β-<span class="text-smallcaps">D</smallcap>-allopyranosyl-(1→4)-O-2,6-dideoxy-3-O-methyl-β-<smallcap>D</smallcap>-arabino-hexopyranosyl-(1→4)-2,6-dideoxy-3-O-methyl-β-<smallcap>D</span>-ribo-hexopyranosyl)oxy]-14-hydroxy-12-[(1-oxo-3-phenyl-2-propen-1-yl)oxy]-, (3β,11α,12β,14β)-
- Pregnan-20-one, 11-(acetyloxy)-3-[(O-6-deoxy-3-O-methyl-β-<span class="text-smallcaps">D</smallcap>-allopyranosyl-(1→4)-O-2,6-dideoxy-3-O-methyl-β-<smallcap>D</smallcap>-arabino-hexopyranosyl-(1→4)-2,6-dideoxy-3-O-methyl-β-<smallcap>D</span>-ribo-hexopyranosyl)oxy]-14-hydroxy-12-[(1-oxo-3-phenyl-2-propenyl)oxy]-, (3β,11α,12β,14β)-
Condurangoglykosid A is a natural product and an anticancer drug that has shown to be effective in the treatment of prostate cancer. This drug inhibits the growth of tumour cells by preventing necrosis factor from binding to the cell membrane, which prevents the release of cytochrome C from mitochondria. Condurangoglykosid A also protects liver cells from damage and death by inhibiting toxins that are released into the body during cancer treatment. Condurangoglykosid A also inhibits tumor growth by blocking nuclear factor kappa-light-chain-enhancer (NFκB) activation in cancer cells. This drug can be administered orally and has been shown to be safe for human use. It has been observed that Condurangoglykosid A may have an antitumor effect on cervical cancer cells, but this has not been confirmed yet.
Proprietà chimiche
Richiesta tecnica su: 3D-LAA05190 Condurangoglykosid A
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.
